文献速递血栓与止血

艾曲泊帕与罗米司亭治疗成人原发免疫性血小板减少症的血栓风险比较

Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag vs romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) cohort.
PubMed 文献 · J Thromb Haemost · 2026-04-10

基于法国国家医疗数据库的靶试验模拟研究,纳入2011至2022年首次使用TPO受体激动剂的成人原发免疫性血小板减少症患者,比较艾曲泊帕与罗米司亭的1年血栓风险。艾曲泊帕组1年加权累积血栓发生率为5.1%(95%CI 3.6%-6.6%),罗米司亭组为1.9%(95%CI 1.0%-2.7%),校正后风险比1.93(95%CI 1.11-3.34)。前6个月未见显著差异,此后差异显现,≥75岁患者风险差异最大。

要点

  • 艾曲泊帕1年血栓风险高于罗米司亭,校正HR为1.93(95%CI 1.11-3.34)。
  • 暴露6个月内两组无显著差异,之后差异才显现且由少数事件驱动。
  • ≥75岁患者两药血栓风险差异最大,老年患者选择TPO-RA需权衡。

核心结论

  • 艾曲泊帕暴露超过6个月后血栓风险高于罗米司亭,老年患者差异尤为明显。

研究设计与样本

  • 靶试验模拟研究,使用法国国家医疗数据库,比较首次使用TPO-RA的成人原发免疫性血小板减少症患者。
  • 艾曲泊帕组2761例,罗米司亭组949例,随访至血栓首次住院、停药、死亡或1年随访结束。
  • 采用逆概率治疗加权及含时变校正的Cox比例风险模型。

主要发现

  • 1年加权累积血栓发生率:艾曲泊帕5.1%(95%CI 3.6%-6.6%),罗米司亭1.9%(95%CI 1.0%-2.7%)。
  • 艾曲泊帕对比罗米司亭1年校正风险比为1.93(95%CI 1.11-3.34)。
  • 前6个月无显著差异,此后差异显现且由少数事件驱动;静脉与动脉血栓分别分析结果相似。
  • ≥75岁患者风险差异最大。
  • 罗米司亭组患者年龄更大、血栓危险因素更多。

临床怎么用

  • 对需长期使用TPO-RA的成人原发免疫性血小板减少症患者,尤其≥75岁者,选择药物时应考虑艾曲泊帕相对更高的血栓风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombopoietin receptor agonists (TPO-RAs) have been identified as a risk factor for thrombosis in immune thrombocytopenia. A potential risk difference between eltrombopag and romiplostim (the only TPO-RAs available in France) is unknown and may be due to pharmacological differences. OBJECTIVES: We aimed to compare the risk of thrombosis between eltrombopag and romiplostim in adult patients with primary immune thrombocytopenia. METHODS: We performed a target trial emulation using the French national healthcare database. Patients exposed to first-line TPO-RAs were followed until the first hospitalization for thrombosis, discontinuation of TPO-RAs, death, or the end of follow-up at 1 year. We used inverse probability of treatment weighting and performed Cox proportional hazards models with time-varying adjustment. RESULTS: Between 2011 and 2022, 2761 and 949 patients were included in the eltrombopag and romiplostim groups, respectively. Patients in the romiplostim group were older and had more risk factors for thrombosis. The 1-year weighted cumulative incidence of thrombosis was 5.1% (95% CI, 3.6%-6.6%) with eltrombopag and 1.9% (95% CI, 1.0%-2.7%) with romiplostim. The adjusted hazard ratio for eltrombopag vs romiplostim was 1.93 (95% CI, 1.11-3.34) at 1 year. No significant difference was observed in the first 6 months, but emerged thereafter due to a few events. Results were similar for venous and arterial thrombosis when considered separately. The risk difference was the greatest in patients aged ≥75 years. CONCLUSION: Eltrombopag was associated with a greater risk of thrombosis than romiplostim after 6 months of exposure, particularly in elderly patients.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Zordan J, Zadro Y, Sommet A, et al. Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag vs romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) cohort. J Thromb Haemost. 2026. PMID: 41967713. doi:10.1016/j.jtha.2026.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。